Human protein phosphatase-1 (PP1) isoforms, PP1α, PP1β, PP1γ1 and PP1γ2, differ in primary sequences at N-and C-termini that potentially bind cellular regulators and define their physiological functions. The GLC7 gene encodes PP1 catalytic subunit with >80% sequence identity to human PP1 and is essential for viability of Saccharomyces cerevisiae. In yeast, Glc7p regulates glycogen and protein synthesis, actin cytoskeleton, gene expression and cell division. We substituted human PP1 for Glc7p in yeast to investigate the ability of individual isoforms to catalyze Glc7p functions. S. cerevisiae expressing human PP1 isoforms were viable. PP1α-expressing yeast grew more rapidly than strains expressing other isoforms. On the other hand, PP1α-expressing yeast accumulated less glycogen that PP1β-or PP1γ1-expressing yeast. Yeast expressing human PP1 were indistinguishable from WT yeast in glucose derepression. However, unlike WT yeast, strains expressing human PP1 failed to sporulate. Analysis of chimeric PP1α/β subunits highlighted a critical role for their unique N-termini in defining PP1α and PP1β functions in yeast. Biochemical studies established that differing association of PP1 isoforms with the yeast glycogen-targeting subunit, Gac1p, accounted for their differences in glycogen synthesis. In contrast to human PP1 expressed in E. coli, enzymes expressed in yeast displayed in vitro biochemical properties closely resembling PP1 from mammalian tissues. Thus, PP1 expression in yeast should facilitate future structure-function studies of this protein serine/threonine phosphatase.
2 regulator (13) and also identified novel Glc7p-regulated events in yeast (10, 14) . These studies also emphasized the conservation of PP1 structure and regulation in eukaryotes.
As in higher eukaryotes, Glc7p regulates multiple physiological events in yeast, including glycogen metabolism (9) , sporulation (15) and transcriptional responses (16) . Thus, analysis of GLC7 phenotypes provides a broad readout of PP1 functions. We utilized a gene replacement strategy to substitute Glc7p in S. cerevisiae with human PP1 isoforms. These studies established that human PP1 supported growth and viability of yeast in the absence of GLC7. Additional studies highlighted differences in the assembly of human PP1 isoforms into functional complexes containing yeast PP1 regulators, thereby accounting for their differing ability to control aspects of yeast physiology. These studies provided the direct experimental evidence for distinct physiological roles of PP1 isoforms and highlighted structural elements at their N-termini that may direct PP1 functions in eukaryotic cells.
Most structural and biochemical studies of human PP1 have focused on enzymes expressed in Escherichia coli (17) . These Mn 2+ -requiring enzymes differ from native PP1 purified from mammalian tissues, which contains Zn 2+ and Fe
2+
in the active site, and showed enhanced dephosphorylation of p-nitrophenyl phosphate (pNPP) (18) and impaired regulation by proteins such as inhibitor-1 (19) and neurabins (20) . While expression in insect cells (20, 21) and Pichia pastoris (18) yielded PP1 with improved biochemical characteristics, low yield (20) and insolubility (21) of these overexpressed proteins has severely limited the widespread use of these eukaryotic expression systems. Human PP1 expressed in S. cerevisiae demonstrated biochemical properties more closely resembling PP1 from mammalian tissues than the enzyme expressed in E. coli, and provided a novel expression system that should greatly facilitate future mechanistic studies of this protein serine/threonine phosphatase. Yeast Strains -Yeast strains (Supplemental table 1) were derived from the parent strain, KT1900 strain and were congenic with KT1112 (MATa ura3-52 leu2 his3) (22) . Yeast were grown on YPD (2% tryptone, 1% yeast extract and 2% glucose) medium (BD Biosciences) at 30°C except when noted. Complete synthetic medium (CSM) and media lacking specific amino acids were prepared with yeast nitrogen base (BD Biosciences), 2% glucose, amino acid supplement mixtures (QBiogene) and copper sulfate added when needed. Yeast strains were sporulated at 24°C on solid medium containing 1% potassium acetate, 0.1% yeast extract and 0.05% dextrose. Strains transformed with plasmid pNC160 (JG1-15) lost GFP-Glc7p-expressing plasmid when grown on SC-Trp plates (which retained pNC160) and 1 mg/mL 5-fluoroorotic acid (5-FOA) (Toronto Research Chemicals) for counterselection.
MATERIALS AND METHODS

Materials
PP1 genotypes were confirmed by colony PCR and expression of Glc7p and human PP1 confirmed by immunoblotting yeast lysates. Strains with GLC7 or human PP1 integrated at the HIS3 locus were created by transforming JG24 with integrating plasmid pRS303 (pJG24-29) cut with BstXI within the HIS3 locus. Transformants sporulated, and tetrads were dissected to select JG16-23 strains. Diploid strains, JG25-28, were obtained by mating isogenic haploid mutants. Haploid strains, JG40-49, were generated by integrating the PP1-expressing plasmid into the HIS3 locus of KT1900 and selecting strains for loss of the GFP-Glc7p-expressing maintenance 3 plasmid by growth on CSM containing 5-FOA. JG50 was created by integrating pRS303 plasmid into JG51, and pRS316 plasmid eliminated by growth on CSM containing 5-FOA.
Expression Plasmids -Primers (Supplemental Table 2 ) were utilized to generate mutant PP1 cDNAs that were inserted into expression plasmids (Supplemental Table 3 ). The CUP1 promoter was used to express Glc7p and human PP1 catalytic subunits in yeast with the exception of plasmids derived from pJG24-29, which used the native GLC7 promoter and terminator (derived from p1855). Haemagglutinin (HA) tag was inserted into selected plasmids (pJG9, 11, 13, 15 and 17) . Chimeras of PP1α and PP1β used twostep PCR with PP1α N-and C-terminus with overlapping PP1β catalytic core sequences (JAG143-146) and PP1α catalytic core with overlapping PP1β N-or C-terminus (JAG143 & 148 or JAG147 & 146). All PCR products were purified, cut with EcoRI and ligated into pNC160.
Fluorescence
Microscopy -Indirect immunofluorescence of yeast was as described (23) . Log phase yeast, fixed in 4% formaldehyde and permeabilized in solution B (100 mM K 2 PO 4 pH 7.5 and 1.2 mM Sorbitol) containing ~450 U of lyticase (Sigma) and 0.5% 2-mercaptoethanol, were stained with rabbit anti-HA antibody (Roche) at 1:200 dilution and Cy3-conjugated goat antirabbit secondary antibody at 1:200 dilution (Jackson Immunoresearch Laboratories) and costained with 4,6-diamidino-2-phenylindole (Sigma) or rabbit anti-histone H2A antibody (1:200) to visualize nuclei. Zeiss Imager A1 Axioscop was used with the images captured on Hamamatsu ORCA ER digital camera interfaced with MetaMorph software (Universal Imaging, Silver Spring, MD).
Yeast Phenotypes -Glycogen accumulation was estimated by patching yeast on CSM plates at 30°C for 24 or 48 hours. Plates were inverted over iodine crystals to stain glycogen and photographed. DH3 (deletion of glycogen synthase), EG328-1A (the parent strain) and WW10 (deletion of both PCL8 and PCL10) were used as reference for low, normal and high levels of glycogen. Glucose derepression was performed as described (24) . Plates were incubated at 30°C under anaerobic conditions (chambers provided by Annette Golonka, Duke U.). All yeast phenotypic studies were undertaken using at least 6 independent colonies.
Yeast Glycogen Content -Quantitative glycogen assays were performed as described (25) with the following changes. Culture growth was supplemented with 0.1 mM CuSO 4 as indicated. Total glucose was analyzed using Amplex Red glucose assay kit (Molecular Probes).
PP1 Catalytic Subunits -Recombinant PP1 catalytic subunits were expressed in E. coli as described (26). Native PP1 catalytic subunits were purified from rabbit skeletal muscle (27). PP1 catalytic subunits were partially purified from yeast strains. Yeast were grown at 30°C to OD 600 of 0.6-0.8 and PP1 expression induced with 1 mM CuSO 4 for 3-4 hours prior to sedimenting yeast by centrifugation. The yeast pellet was resuspended in YeastBuster Protein Extraction Reagent and THP solution (Novagen) that included protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1 mM benzamidine, 1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin A) and lysed as described by manufacturer. Lysed yeast were subjected to centrifugation at 30,000xg for 30 min at 4°C, and purified via heparin-agarose essentially as previously described (26). Most studies utilized batch elution with 0.5 M NaCl following extensive washing with 0.1 M NaCl and yielded PP1 catalytic subunits with 50-55% purity. Elution using a linear gradient from 0.1 to 0.5 M NaCl (26) or affinity purification on MicrocystinSepharose (Supplemental Figure3) increased the enzyme purity to greater than 70-80%.
Phosphorylase a Phosphatase -Enzyme assays were undertaken as previously described (26). Recombinant PP1 Regulators -GST-Gac1p, GST-Gip2p, GST-Pig2p and GST-neurabin (NrbI) (374-516) fusion proteins were expressed in E. coli and purified as previously described (5) . Immunoreactivity was quantified using anti-mouse AlexaFluor 680 (Molecular Probes) and anti-rabbit IR Dye 800 (Rockland) secondary antibodies respectively using Odyssey infrared imaging system (Li-COR Biosciences).
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RESULTS
Yeast Strains Expressing Human PP1
Primary structures of human and S. cerevisiae PP1 ( Figure 1A ) highlight a highly conserved catalytic core (filled bars) flanked by diverse N-and C-termini (open bars). To compare functional properties of the human and yeast PP1 catalytic subunits, we transformed GLC7:LEU2 (KT1900 and KT1901) strains with plasmids expressing HA-PP1 catalytic subunits under the inducible CUP1 promoter and selecting on CSM containing 5-FOA to eject the GFP-Glc7p maintenance plasmid. This generated strains that expressed individual WT human PP1 isoforms, a C-terminally truncated PP1α306 and chimeric PP1α/β catalytic subunits that substituted either N-or C-termini from PP1α into PP1β and vice versa (schematically shown in Figure 1B) .
Immunoblotting yeast lysates with anti-HA antibody allowed for direct comparison of expression levels of all PP1 catalytic subunits ( Figure 2A ). Quantitation using Odyssey showed that basal expression of HA-Glc7p was 4 to 5-fold higher than any human PP1 ( Figure 2B ). Addition of 0.1 mM CuSO 4 to media increased expression of all PP1s by 2 to 3-fold but not a control protein, PGK. Growth on media containing 0.3 mM CuSO 4 resulted in a further 0.2-2-fold increase in human PP1, but the expression of HA-Glc7p was either unchanged on modestly reduced when compared with growth in 0.1 mM CuSO 4 . This suggested that there was an upper limit for PP1 expression beyond which viability may be compromised (28).
Prior studies that expressed GFP-Glc7p in yeast (29) showed localization at bud neck and spindle poles. By contrast, HA-Glc7p was highly concentrated at nuclei (Supplemental Figure 1) . While cytoplasmic distribution was also noted, no immunofluorescence for HA-Glc7p was seen at bud neck or spindle poles. This may reflect the differing experimental strategies with the overexpression of GFP-Glc7p in the earlier studies compared to gene replacement used in current work. Compared to Glc7p, fewer yeast showed nuclear staining for human PP1, with PP1α most consistently localized to nuclei and PP1γ1 and PP1γ2 being excluded from nuclei in most cells. While nuclear staining for human PP1 was variable, all yeast showed immunostaining for histone H2A. This suggested that as in mammalian cells, PP1 localization in yeast may be highly dynamic (29). Differences in PP1 isoforms was also suggested by frequent nucleolar localization of PP1β and PP1α, PP1β and PP1γ1 at mitotic spindles and PP1β and PP1γ2 at bud scars.
Growth of Human PP1-Expressing Yeast
Analysis of growth of multiple independent colonies showed that yeast expressing HA-Glc7p grew essentially like control WT yeast ( Figure 3 ). By comparison, all yeast expressing human PP1 catalytic subunits grew more slowly. Among these, yeast expressing PP1α or PP1α306 grew most rapidly and PP1β-expressing yeast grew the slowest. Similar results were obtained on liquid or solid media and rich or synthetic media (data not shown). Yeast expressing chimeric PP1 subunits, specifically PP1α/βC with C-terminus from PP1β fused to the remainder of PP1α and PP1β/αN, containing the N-terminus of PP1α, grew almost 2-fold faster than yeast expressing PP1β, PP1β/αC or PP1α/βN ( Figure 3B ). These data suggested that deleting the C-terminus (PP1α306) or substituting the C-terminus from PP1β had little effect on PP1α's ability to support yeast growth. Hence, PP1α, PP1α306, PP1β/αN and PP1α/βC-expressing yeast grew at essentially similar rate. By contrast, PP1α/βN, containing the N-terminus from PP1β, grew more slowly and resembled yeast expressing either PP1β or PP1β/αC. These data highlighted a unique contribution of N-terminal sequences in PP1α and PP1β in directing yeast growth.
Rank order of growth of yeast expressing Glc7p and human PP1 isoforms in media containing 0.1 mM CuSO 4 was identical to that in media lacking CuSO 4 ( Figure 3A ). However, discernable reduction in growth of yeast containing HA-Glc7p was observed at 0.1 mM CuSO 4 (approx. 15%) and 0.3 mM CuSO 4 (30% -data not shown). As growth of untransformed or WT yeast was unaffected by either 0.1 mM or 0.3 mM CuSO 4 , this hinted at a growth inhibitory effect of high Glc7p levels (9) . Hence, growth on 0.3 mM CuSO 4 no longer differentiated yeast expressing Glc7p from those with human PP1.
We also generated yeast in which HA-PP1 cDNAs (behind CUP1 promoter) were inserted into an identical HIS3 locus. HA-Glc7p levels in the integrated strain were 3-4-fold higher than those expressing human PP1, similar to noted above for plasmid-borne strains (data not shown). This suggested either enhanced translation or stability of Glc7p rather than gene dosage accounting for its higher levels in yeast. Most importantly, yeast containing integrated HA-PP1, either in presence or absence of CuSO 4 , grew identically to strains containing PP1-expressing plasmids (data not shown).
When compared at differing temperatures, WT S. cerevisiae, like yeast expressing HA-Glc7p, grew effectively on solid media at 16°C ( Figure  4A ), 30°C ( Figure 4B ) and 37°C ( Figure 4C ). By comparison, yeast expressing human PP1, both WT and chimeras, grew slower with fewer colonies seen at higher dilutions at all temperatures. Yeast expressing PP1β, PP1α/βN and PP1β/αC were notably impaired in growth at 37 o C, which was readily visible at lower dilutions. This highlighted the unique temperature sensitivity of yeast expressing PP1β and PP1α/βΝ α, and suggested a key contribution of the unique PP1β N-terminus to this phenotype.
Ion homeostasis in yeast is known to regulated by Glc7p (30,31). In contrast to WT and HA-Glc7p-expressing yeast, yeast expressing human PP1 catalytic subunits either failed to grow or grew slowly in media containing 0.1 M CsCl ( Figure 5A ) or 0.9 M NaCl ( Figure 5B ). Interestingly, strains expressing the chimeric PP1β/αN catalytic subunit showed significant growth on media containing 0.1 mM CsCl. Thus, the fusion of PP1β N-terminus to the remainder of PP1α generated a unique human PP1 catalytic subunit that showed some capacity to regulate yeast ion homeostasis.
Glycogen Accumulation in Yeast Expressing Human PP1
Glc7p is essential for glycogen synthesis (22) and promotes the dephosphorylation and activation of yeast glycogen synthase. Thus, glycogen accumulation, visualized in yeast by iodine staining (Figure 6A ), showed that less glycogen accumulated in yeast expressing human PP1 than either control yeast or yeast expressing HA-Glc7p. Despite similar PP1 levels, yeast expressing human isoforms also demonstrated differing glycogen content. Specifically, PP1β−, PP1γ1-and PP1γ2-expressing yeast accumulated more glycogen than yeast containing either PP1α or PP1α306. PP1α306-expressing yeast consistently showed a small increase in glycogen content compared to PP1α-expressing yeast, suggesting a potential negative role for PP1α C-terminus in generating an active glycogen synthase phosphatase.
Yeast expressing a chimeric phosphatase, PP1α/βN, showed increased glycogen content compared to PP1α-expressing yeast, demonstrating the ability of the PP1β N-terminus to enhance PP1α's capacity to promote glycogen synthesis. Conversely, incorporation of PP1α Nterminus generatedPP1β/αN and reduced PP1β's activity in promote yeast glycogen accumulation. By comparison, PP1β/αC accumulated glycogen to similar levels as yeast expressing PP1β. These data emphasized the positive role for the Nterminus in PP1β's ability to regulate yeast glycogen. When yeast were grown on media 6 containing CuSO 4 to increase PP1 levels, the overall glycogen content in all strains was elevated but this did not alter the overall conclusion, namely the N-terminus accounted for PP1β's unique ability to promote yeast glycogen synthesis.
A quantitative assay that analyzed total glucose following digestion of yeast glycogen with amyloglucosidase ( Figure 6B) 
Binding of Human PP1 to Yeast PP1 Regulators
Gac1p is the primary PP1 targeting subunit controlling yeast glycogen synthesis (32). We utilized purified recombinant GST-Gac1p in pulldowns from lysates of yeast that were matched for their content of human PP1. To our surprise, Gac1p bound human PP1β, PP1γ1 and PP1γ2 with near equal efficiency to Glc7p, when normalized for input PP1 (Figures 7A and 7B) . By contrast, GST-Gac1p sedimented 5-fold less PP1α (and PP1α306). With the exception of Glc7p, the relative binding of GST-Gac1p to human PP1 isoforms paralleled the glycogen accumulation seen in yeast expressing these proteins.
Binding of chimeric PP1α/β catalytic subunits by varying concentrations of GST-Gac1p ( Figure 7B ) confirmed that PP1β bound GSTGac1p with near equal affinity to Glc7p. By contrast, GST-Gac1p demonstrated approximately 5-fold reduced affinity for PP1α. PP1β/αC showed Gac1p binding equal to or better than PP1β. By comparison, PP1β/αN showed reduced Gac1p binding, that was indistinguishable from PP1α. Similarly, PP1α/βC bound Gac1p similar to PP1α, while PP1α/βN showed enhanced Gac1p binding, equivalent to PP1β. These data also highlighted the unique contribution of PP1β N-terminus in enhancing Gac1p binding. By comparison, the presence of PP1α N-terminus diminished Gac1p binding. By comparison, the C-termini of human PP1 catalytic subunits appeared to be largely dispensable for Gac1p binding.
Two other yeast PP1 regulators, Gip2p and Pig2p, have also been implicated in regulating glycogen metabolism (30,32). We analyzed the binding of Human PP1 to purified GST-Gip2p and GST-Pig2p ( Figure 7A ). Remarkably, PP1α and even more striking, PP1β, bound GST-Gip2p more effectively than Glc7p. By comparison, GSTGip2p bound PP1γ1, PP1γ2 and PP1α306 similar to or slightly weaker than Glc7p ( Figure 7C ). All human PP1s bound GST-Pig2p with equivalent efficacy but 2-fold weaker than Glc7p ( Figure 7C ). Lack of correlation between PP1 binding and glycogen accumulation suggested that yeast complexes containing Pig2p and Gip2p do not account for the differences in glycogen content noted in yeast expressing human PP1 isoforms.
Human PP1 Supports Selected Glc7p Functions
Glc7p binds Gip1p to regulate yeast sporulation (33 Figure 2) . By comparison, the yeast strain KT1512, that lacked Reg1p, grew well (35). These data suggested that human PP1 isoforms were indistinguishable from Glc7p in regulating glucose derepression.
Biochemical Analysis of Human PP1 Expressed in Yeast
As current studies represented the first expression of human PP1 in budding yeast, we analyzed the biochemical properties of PP1 partially purified from yeast as previously described (11) (12) (13) . Phosphorylase phosphatase activity of human PP1 preparations was potently inhibited by 2 nM microcystin-LR (MCLR), a known PP1 inhibitor (36) ( Table 1) . Moreover, unlike human PP1α306 expressed in E. coli, PP1 catalytic subunits from yeast did not require MnCl 2 for activity and were not inhibited by 10 mM EDTA (17), resembling PP1 purified from rabbit skeletal muscle (data not shown). Unlike bacterially expressed PP1α306, whose activity against pNPP was inhibited by 2 nM MCLR, PP1 from rabbit skeletal muscle showed no detectable hydrolysis of pNPP. While partially purified human PP1 from yeast displayed pNPP phosphatase activity, this was not inhibited by MCLR and thus, represented contaminating yeast phosphatase(s).
Dose-response for inhibition of human PP1 expressed in yeast by okadaic acid was essentially identical with IC 50 of approximately 80 nM and significantly higher than PP2Ac purified from skeletal muscle (IC 50 1 nM - Figure 8A ). Human and yeast PP1 catalytic subunits were potently inhibited by human inhibitor-2 (I-2), a known PP1-specific inhibitor and as anticipated, PP2Ac was not inhibited by I-2 ( Figure 8B ). Human PP1α expressed in yeast showed 20-fold increased sensitivity to inhibition by GST-NrbI (374-516), another PP1-specific regulator, when compared to the same enzyme expressed in bacteria ( Figure 8C ). Finally, pulldowns with GST-NrbI (374-516) showed that this PP1-binding peptide (5) bound human PP1γ1 from yeast lysates with nearly 50-fold higher affinity than PP1β, which was barely detectable using 10 µg of the bait ( Figure 8D ). These data demonstrated that relative recognition of human PP1 isoforms expressed in yeast by neurabin displayed the isoform selectivity noted in mammalian neurons (5) . Together, these studies demonstrated that human PP1 expressed in S. cerevisiae displayed biochemical properties that closely resembled those of PP1 from mammalian tissues.
DISCUSSION
Most eukaryotes contain multiple PP1 genes. Thus, PP1 is encoded by 4 genes in Drosophila melanogaster, 3 mammalian genes, 7 to 11 plant genes and up to 38 Caenorhabditis elegans genes. Multiple PP1 isoforms, PP1α, PP1β, PP1γ1 and PP1γ2, are expressed in mammalian tissues, albeit that PP1γ2 is most highly expressed in testes and PP1β is the major isoform in skeletal muscle (37). Eukaryotic cells also contain more than 60 PP1 regulators. Thus, investigating the physiological role of PP1 isoforms and/or the molecular basis by which they are recruited by cellular regulators is challenging. Thus, it is currently unclear whether high levels of G M (PPP13A) and PP1β or specific structural determinants in these two proteins promote their preferential association and define PP1β/G M as a glycogen synthase phosphatase (8) .
Expression of cellular PP1 regulators is closely linked to the content of PP1 catalytic subunits in mammalian tissues. Thus, deleting mouse G M (PPP13A) gene resulted in 60% reduction of overall muscle PP1 activity (38 2+ ions, but N-and C-termini unique to each PP1 isoform were not visualized. Cocrystallization of PP1 with a fragment of the myosin-targeting subunit (MYPT1) (44) and mutagenesis studies (20) hinted at a role for the PP1 C-terminus in binding cellular regulators. By contrast, inability to modify N-terminal sequences without compromising bacterial PP1 expression or inactivating the phosphatase (J.H. Connor and S. Shenolikar -unpublished data) has hampered efforts to investigate the role of N-terminal sequences in PP1 function and regulation.
Presence of an essential gene, GLC7, encoding a single PP1 catalytic subunit in S. cerevisiae facilitated genetic studies that have helped to define the mode of action of several human PP1 regulators (11) (12) (13) . This also suggested conserved PP1 function and regulation in this model eukaryote. Thus, current studies undertook a gene replacement strategy to generate yeast strains expressing individual human PP1 isoforms. Lower levels of human PP1, even in yeast were grown on media containing CuSO 4 to induce PP1 controlled by the CUP1 promoter, suggested a more efficient translation or increased stability of Glc7p in yeast. Consistent with their reduced PP1 content, yeast expressing human PP1 isoforms grew 3-to 5-fold slower than untransformed yeast or yeast expressing HA-Glc7p. The 4-fold faster growth for PP1α-expressing compared to PP1β-expressing yeast enabled structure-function studies that analyzed PP1α/β chimeras expressed in yeast. Substituting PP1β N-terminus in PP1α/βN reduced yeast growth while substituting the PP1α N-terminus enhanced growth in PP1β/αN-expressing yeast. By contrast, switching Cterminal sequences in these two PP1 isoforms had little or no effect of growth. These studies not only noted the differing ability of human PP1 isoforms to support yeast growth but also for the first time, highlighted a critical role for their unique Nterminal sequences in dictating the cellular function of PP1 catalytic subunits.
Immunofluorescence showed that the highest concentration of human PP1 was in the yeast nuclei. Human PP1γ1 was uniquely associated with yeast mitotic spindles, as also reported in HeLa cells (46). Nucleolar localization of human PP1β in yeast was also consistent with prior observations in mammalian cells (47). Interestingly, the latter studies focused an Nterminal arginine present in PP1β and PP1γ1 as was critical for their nucleolar localization. While PP1α was excluded from this compartment, the substitution, Q20R, successfully targeted this enzyme to nucleoli. Thus, specific N-terminal residues may play a key role in directing the subcellular localization of PP1 isoforms in both human and possibly yeast cells.
Yeast expressing human PP1 accumulated less glycogen than strains expressing Glc7p. PP1α strains were particularly notable in that they accumulated less glycogen than strains expressing other human isoforms. However, increasing PP1α expression by yeast growth on media containing CuSO 4 appeared to overcome this deficit and may be explained by the reduced affinity of PP1α for the yeast glycogen-targeting subunit, Gac1p. Analysis of PP1α/β chimeras showed that PP1β's enhanced ability to bind Gac1p and promote glycogen accumulation resulted from its unique N-terminus. Thus, PP1α/βN bound Gac1p more avidly than PP1α, while PP1β/αN showed reduced Gac1p binding compared to PP1β. Interestingly, studies in yeast that expressed a mutant Glc7p, R19A/K22A, showed that this strain failed to accumulate glycogen (48), and speculated that N-terminal residues may mediate Gac1p binding. It is noteworthy that R19 is present Glc7p and human PP1β, PP1γ1 and PP1γ2, which bound Gac1p with avidity similar to Glc7p. By comparison, as noted above, PP1α possessed glutamine and bound Gac1p weakly. Thus, specific N-terminal residues that mediate PP1 binding to cellular regulators may also dictate its localization in cells.
9
The ability of Glc7p to bind Gac1p with similar avidity to human PP1β, PP1γ1 and PP1γ2 was somewhat surprising as Glc7p-expressing strains accumulated 5-fold higher glycogen. This could reflect the unique activity of the Glc7p/Gac1p complex to regulate yeast glycogen synthase phosphatase. Thus, there appears to be some discordance between binding of regulators and generation of a functional PP1 complex. This was also suggested in prior studies that identified PP1 mutations that retained effective neurabin binding, but compromised neurabin's ability to regulate phosphatase activity (26). In contrast to Gac1p, the pattern of human PP1 binding to Gip2p and Pig2p, also implicated in yeast glycogen metabolism (30,32), did not correlate with the glycogen content in yeast and discounted these interactions as primary drivers of yeast glycogen accumulation.
Earlier in vitro studies had suggested that PP1 C-termini may play in regulation by cellular proteins (49). However, current work failed to note significant functional consequences of deleting or substituting C-terminal sequences in human PP1. Similarly, a C-terminal deletion in Glc7p (glc7-305) appeared fully functional in promoting yeast glycogen synthesis, although a further truncation, glc7-299, did confer partial glycogen deficiency (48). This may reflect the fact that the PP1 C-terminus may play paradoxical role in regulating PP1, potentially inhibiting phosphatase activity of the isolated catalytic subunits (50), while contributing positively to allosteric modulation of PP1 by cellular regulators (20, 49) .
It is noteworthy that yeast expressing human PP1 did not sporulate, a known Glc7p-regulated event (51). These strains also showed increased salt and temperature sensitivity compared to WT yeast, possibly indicating the reduced ability of human PP1 to bind or be regulated by selected yeast PP1-binding proteins. On the other hand, despite their lower expression in yeast, all human PP1 isoforms effectively catalyzed the events required for glucose derepression. This suggested that human PP1 may recruit some yeast regulators, such as Reg1p (35) as effectively or better than Glc7p.
As current studies represented the first expression of human PP1 in budding yeast, we also analyzed the biochemical properties PP1 partially purified from yeast lysates. Unlike human PP1 expressed in E. coli, these enzymes did not require added divalent cations, specifically Mn 2+ , were not inhibited by EDTA and did not display detectable microcytin-LR-inhibited pNPP phosphatase activity. Sensitivity of PP1 enzymes purified from yeast to both okadaic acid and inhibitor-2 were entirely characteristic of PP1 isolated rabbit skeletal muscle. Finally, human PP1 expressed in yeast showed 50-fold higher sensitivity to the neuronal regulator, neurabin, which also selectively recruited PP1γ1 over PP1β from yeast lysates as previously seen in mammalian neurons. This raises the intriguing possibility that the generation of yeast strains expressing human PP1 provides a novel expression system that may provide both quantity and quality of human PP1 necessary to facilitate future studies directed at a better understanding of the structure and regulation of this key signaling molecule.
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